Scott Helberg
Pulmonary Disease · Yankton, SDNPI 1619173945
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $513,095 of the $621,269 with a category attached, or 82.6%. AstraZeneca accounts for 81.8% of it on its own, with 16 other manufacturers making up the rest. Among pulmonary disease clinicians in SD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 725 payments — averaging $856.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$508K
- GSK$75K
- Amgen$36K
- Johnson & Johnson$1K
- Regeneron Healthcare Solutions, Inc.$97
- Insmed, Inc.$57
- plus $368 from 11 others
What the payments were for
- Speaking & faculty fees$513,09583%
- Travel & lodging$92,38315%
- Food & beverage$15,6893%
- Education$1020%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 539 | $508,412 |
| GSK | 112 | $75,268 |
| Amgen | 34 | $35,631 |
| Johnson & Johnson | 8 | $1,436 |
| Regeneron Healthcare Solutions, Inc. | 4 | $97 |
| Insmed, Inc. | 4 | $57 |
| Merck | 4 | $50 |
| Boehringer Ingelheim | 4 | $50 |
| Baxter Healthcare | 3 | $47 |
| Genentech, Inc. | 1 | $46 |
| Advanced Respiratory, Inc | 3 | $42 |
| Resmed Corp | 2 | $37 |
| Sunovion Pharmaceuticals Inc. | 2 | $26 |
| Mylan Specialty L.p. | 2 | $25 |
| Sanofi | 1 | $18 |
| Mallinckrodt Enterprises LLC | 1 | $15 |
| United Therapeutics Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEZSPIRE$422,298
- FASENRA$112,006
- TRELEGY ELLIPTA$46,614
- Monarch Platform$1,309
How this compares
$621,269 in reported general payments places this provider in the 95th percentile of 35 pulmonary disease providers in South Dakota.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 136 | $112,130 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $19,359 |
| Arnuity ElliptaFluticasone Furoate | 23 | $4,379 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 26 | $747 |
| Azithromycin | 15 | $538 |
| Omeprazole | 15 | $255 |
| Ropinirole Hcl | 15 | $215 |
| Pantoprazole Sodium | 16 | $186 |
| Montelukast Sodium | 15 | $78 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $75,268 | $135,868189 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 35 pulmonary disease providers in South Dakota.
Other pulmonary disease in Yankton
- Michael PietilaYankton$79K
- Lori HansenYankton$10K
- Svien SenneWatertown$13K
- Joevasanth DevasahayamSioux Falls$8K
- Matthew TaylorSioux Falls$8K
- Cliff JanikowskiRapid City$6K
- Fady JamousSioux Falls$6K
- Rizan HajalSioux Falls$5K
- Deptmer AshleyAberdeen$5K
- Kaitlin BranickSioux Falls$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.